Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07140770

Conditions

Physical Activity

Sleep

Allogenic Hematopoietic Cell Transplant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fitbit

Questionnaire

Study Details

Brief summary:

To understand the changes in health-related quality of life of patients and caregivers after allogeneic hematopoietic cell transplantation.

Conditions

Physical Activity

Sleep

Allogenic Hematopoietic Cell Transplant

Study ID

NCT07140770

Start date

Sep 2, 2025

Status verified date

Mar, 2026

Completion date

Apr 1, 2028

Anticipated

Primary completion date

Apr 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Eligibility Criteria

  • Participants and caregivers ages 18 years and older.
  • Participants diagnosed with a hematologic malignancy with a scheduled allogeneic HCT.
  • Caregivers identified by participant as the primary caregiver.
  • Participants and caregivers able to read, speak, and consent in English.
  • Participants and caregivers able to understand and be willing to sign a written informed consent document.
  • Participants and caregivers must have internet access via smart phone or tablet with the capacity to 1) download the Fitbit app and 2) complete study assessments with study

Exclusion Criteria

  • Participant or caregiver unable to provide consent, such as cognitively impaired individuals
  • Participant or caregiver with a diagnosis of sleep apnea.
  • Primary caregiver is a paid professional, such as a live-in Registered Nurse.
  • Participant has multiple caregivers and is unable to identify one primary caregiver.

Study Design

Enrollment

66 participants

Anticipated

Interventions and Outcome Measures

Interventions

Fitbit

You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate.

Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet.

Questionnaire

Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.

Primary outcome measure

  • Quality of Life Questionnaire [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Eileen D Hacker, MD

713-563-4004ehacker@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Eileen D Hacker, MD

713-563-4004ehacker@mdanderson.org

Principal Investigator:

Eileen D Hacker, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Mar 10, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-03-10.